Saxagliptin vs Teneligliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Saxagliptin · Onglyza
Rights held by AstraZeneca and partners; US product discontinued
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: February 2027 · NCT02969798 (registry estimate)
Reported efficacy
Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)
Result source: NCT00121667
Teneligliptin · Tenelia
Marketed by Tanabe Pharma Corporation and partners
NCT00974090 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.
Reported efficacy
HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)
Result source: NCT01805830
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Saxagliptin | Teneligliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.3%−0.4 vs placeboNCT0075758819 other results
| -0.7% vs -0.0%−0.7 vs placeboNCT0292406412 other results
|
| Body weight, change (kg) | -1.9 vs -0.4−1.5 vs placeboNCT016463207 other results
| —Not posted · NCT01798238 |
| HbA1c below 7% | 44.4% vs 16.6%+27.8 vs placeboNCT0012166715 other results
| —Not posted · NCT01798238 |
| Fasting plasma glucose, change | -0.6 vs -0.3−0.2 vs placeboNCT0075758811 other results
| -0.8 vs 0.2−0.9 vs placeboNCT0292406413 other results
|
| 3-point MACE (% with event) | 7.4% vs 7.4%±0 vs placeboNCT01107886 | —Not posted · NCT01798238 |
HbA1c, change
- Saxagliptin
- -0.7% vs -0.3%−0.4 vs placeboNCT00757588
19 other results
- 7.1% vs 7.5% NCT00661362
- -0.5% vs -0.2% NCT01619059
- -0.8% vs -0.1% NCT01646320
- -0.7% vs -0.1% NCT01128153
- 0.1% vs 0.5% NCT03199053
- -0.7% vs 0.6% NCT01204775
- -1% vs 0.9% NCT01434186
- -1.4% vs -1.0% NCT02419612
- -1.7% vs -1.5% NCT02551874
- -1.0% vs -0.7% NCT02681094
- -1.4% vs -1.1% NCT02284893
- -0.2% vs -0.7% NCT03199053
- 0.1% vs -0.7% NCT03199053
- -0.8% vs -1.0% NCT02471404
- -1.2% vs -1.0% NCT02471404
- -0.8% vs -0.8% NCT02243176
- -0.8% vs -0.8% NCT02243176
- -0.5% vs -0.4% NCT01006590
- -0.4% vs -0.6% NCT01006603
- Teneligliptin
- -0.7% vs -0.0%−0.7 vs placeboNCT02924064
12 other results
- -0.9% vs -0.1% NCT02916706
- -0.6% vs 0.2% NCT00998881
- -0.9% vs 0% NCT02354222
- -0.7% vs 0.3% NCT00974090
- -0.8% vs 0.1% NCT00628212
- -0.8% vs 0.1% NCT00628212
- -0.9% vs -0.3% NCT00971243
- -0.9% vs 0.1% NCT00628212
- -0.8% vs -0.3% NCT00971243
- -0.7% vs -0.3% NCT00971243
- -0.6% vs -0.3% NCT00971243
- -0.9% vs -0.1% NCT02081599
Body weight, change (kg)
- Saxagliptin
- -1.9 vs -0.4−1.5 vs placeboNCT01646320
7 other results
- -3.1 vs 0.9 NCT02419612
- -1.9 vs -0.5 NCT02284893
- -1.5 vs 2.1 NCT02551874
- -2.0 vs -0.4 NCT02681094
- -3.5 vs 1.8 NCT02471404
- -3.1 vs 1.8 NCT02471404
- -1.4 vs -2.0 NCT02243176
- Teneligliptin
- —Not posted · NCT01798238
HbA1c below 7%
- Saxagliptin
- 44.4% vs 16.6%+27.8 vs placeboNCT00121667
15 other results
- 41.1% vs 23.9% NCT00121641
- 43.5% vs 16.6% NCT00121667
- 37.9% vs 23.9% NCT00121641
- 22.1% vs 13.3% NCT00918879
- 45.8% vs 28.8% NCT00698932
- 37.1% vs 16.6% NCT00121667
- 35% vs 23.9% NCT00121641
- 37.5% vs 24.2% NCT00885378
- 21.3% vs 10% NCT03199053
- 36.7% vs 13.3% NCT01646320
- 21.4% vs 11.7% NCT02419612
- 44.3% vs 34.3% NCT02419612
- 37.3% vs 25.1% NCT02284893
- 37.2% vs 26.1% NCT00960076
- 38.3% vs 41.5% NCT02243176
- Teneligliptin
- —Not posted · NCT01798238
Fasting plasma glucose, change
- Saxagliptin
- -0.6 vs -0.3−0.2 vs placeboNCT00757588
11 other results
- -0.5 vs -0.3 NCT01619059
- -1.8 vs -0.3 NCT01646320
- -0.3 vs 0.1 NCT01128153
- 0.1 vs 0.2 NCT03199053
- -1.8 vs -0.6 NCT02284893
- -2.4 vs -1.0 NCT03199053
- -0.6 vs -1.0 NCT03199053
- -1.6 vs -1.5 NCT02471404
- -0.7 vs -1.3 NCT01006603
- -2.1 vs -1.5 NCT02471404
- -1.0 vs -1.0 NCT02243176
- Teneligliptin
- -0.8 vs 0.2−0.9 vs placeboNCT02924064
13 other results
- -1.2 vs -0.1 NCT02916706
- -1.1 vs -0.0 NCT00998881
- -1.1 vs -0.4 NCT01072331
- -1.1 vs -0.4 NCT01072331
- -0.3 vs 0.6 NCT02354222
- -0.8 vs 0.2 NCT00628212
- -0.8 vs 0.2 NCT00628212
- -1.2 vs -0.2 NCT00971243
- -0.9 vs 0.2 NCT00628212
- -1.0 vs -0.2 NCT00971243
- -0.8 vs -0.2 NCT00971243
- -0.9 vs -0.2 NCT00971243
- -0.3 vs 0.4 NCT02081599
3-point MACE (% with event)
- Saxagliptin
- 7.4% vs 7.4%±0 vs placeboNCT01107886
- Teneligliptin
- —Not posted · NCT01798238
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Saxagliptin: 9 of 9 rows · Teneligliptin: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Saxagliptin Rows use multiple source trials | Teneligliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.55 mmol/L @ 24wka,b,c NCT01608724 · Phase 4 · registry result, not featured evidence 1 other source trial-0.62 mmol/L @ 24wk* NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted | -0.69 mmol/L @ 52wk*d,a,b,c NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.4 mg/dL as posted show 1 more dose-0.94 mmol/L @ 52wk* NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17 mg/dL as posted |
| FPG absolute change · mmol/L | -0.29 vs 0.15 placebo mmol/L @ 24wk*b,e,f NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -5.28 mg/dL as posted | -0.96 vs 0.54 placebo mmol/L @ 12wk*b,e,f NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17.3 mg/dL as posted |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.64% (n=229) @ 24wkb,e NCT02104804 · Phase 3 · registry result, not featured evidence · combination | -0.94% @ 24wkteneligliptin 20mgb,e NCT01798238 · Phase 3 · sponsor-reported, not registry data |
| PPG 2H absolute change · mmol/L | -0.77 vs -1.07 Acarbose mmol/L @ 24wka,b,e,f NCT02243176 · Phase 4 · registry result, not featured evidence 2 other source trials-0.65 vs 0.28 placebo mmol/L @ 24wk* NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.66 mg/dL as posted -0.65 vs 0.28 placebo mmol/L @ 24wk NCT01128153 · Phase 3 · registry result, not featured evidence | -2.39 vs 0.33 placebo mmol/L @ 12wk*a,b,e,f NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -43.1 mg/dL as posted |
| PPG 2h Change mg/dL absolute change · mmol/L | -4.08 vs -2.11 placebo mmol/L @ 24wk*b NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted 2 other source trials-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted -1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted | -1.96 vs 0.13 placebo mmol/L @ 24wk*b NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted |
| Dropout rate | 22.7%10 mgg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results25.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 22.9%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 29.6%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 35.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 28.4%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 0% NCT02024477 · Phase 4 · registry result, not featured evidence 10.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 4.5%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT02243176 · Phase 4 · registry result, not featured evidence 17.1% NCT01608724 · Phase 4 · registry result, not featured evidence 2.4% NCT01107886 · Phase 4 · registry result, not featured evidence 19.7%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 19% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 5.7%Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 7.5%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 8.6% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 8.2% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 25% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 6.8%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.5%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.2%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 12.4% NCT01128153 · Phase 3 · registry result, not featured evidence 5.8% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 61.4% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5.6%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 4.3%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 11.8%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 50.6% NCT00614939 · Phase 3 · registry result, not featured evidence 10.8%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 15%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 7.7%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 10.2%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 1%Teneli / Teneli + SUh NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.7%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 19.5%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 11.8%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 7.1%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 9.3%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 7.4%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 10%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 15.9%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20.9%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 11.8%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 21.8%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.8%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 1.2%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 6.2%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.8%10 mgg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results3.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.1%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02024477 · Phase 4 · registry result, not featured evidence 2.2%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 0.3%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT02243176 · Phase 4 · registry result, not featured evidence 2% NCT01608724 · Phase 4 · registry result, not featured evidence — NCT01107886 · Phase 4 · registry result, not featured evidence 4.2%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 1.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 0.4%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence — NCT02551874 · Phase 3 · registry result, not featured evidence · combination 3.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 0.4% NCT02284893 · Phase 3 · registry result, not featured evidence · combination — NCT01204775 · Phase 3 · registry result, not featured evidence — NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 1.7%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 1.9%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01128153 · Phase 3 · registry result, not featured evidence 0.7% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 2.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00918879 · Phase 3 · registry result, not featured evidence —5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 5.9% NCT00614939 · Phase 3 · registry result, not featured evidence —2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 0%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 1.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 1%Teneli / Teneli + SUh NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.6%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 0% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 3.3%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 6.7%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 5.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT01072331 · Phase 3 · registry result, not featured evidence —10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.2%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.2%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 1.3%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 2.5%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.2%10 mgg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results14.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 17%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.8%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.8% NCT02024477 · Phase 4 · registry result, not featured evidence 12.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 7.1%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02243176 · Phase 4 · registry result, not featured evidence 1.8% NCT01608724 · Phase 4 · registry result, not featured evidence 25.5% NCT01107886 · Phase 4 · registry result, not featured evidence 11.4%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 4.1% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 3.8%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.3%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 1.6%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 4.9%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 12.8%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 6.2% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 3.9% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 0% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence 5.1%5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination —Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination 4.4%DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination —Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 4.6%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT01606007 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01128153 · Phase 3 · registry result, not featured evidence 0% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 2.2%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 8.2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 27.1% NCT00614939 · Phase 3 · registry result, not featured evidence 1.4%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 5%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | —Teneli / Teneli + SUh NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results0%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 6.5%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.3%Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 3.2%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 4.7%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.3% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 6.6%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 8%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 3.8%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence 5.7%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.3%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.3%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.6%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 0%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mgg influenza 15.5% (placebo 15.1%) nasopharyngitis 15.5% (placebo 14%) headache 13.3% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results5 mg influenza 16.2% (placebo 15.1%) nasopharyngitis 14.7% (placebo 14%) arthralgia 10.5% (placebo 6.7%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 15.1% (placebo 12.8%) nasopharyngitis 14.6% (placebo 14%) headache 14.1% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg arthralgia 16.3% (placebo 7.4%) headache 16.3% (placebo 16.8%) influenza 15.3% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg upper respiratory tract infection 15.1% (placebo 15.8%) urinary tract infection 13.2% (placebo 8.4%) headache 12.3% (placebo 16.8%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 13.7% (placebo 8.4%) upper respiratory tract infection 11.8% (placebo 15.8%) influenza 10.8% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5mg and 10mg nasopharyngitis 9.9% NCT02471404 · Phase 4 · registry result, not featured evidence · combination hyperlipidaemia 6.2% hyperlipidaemia 3.7% abdominal distension 1.2% NCT02243176 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 2.7% dizziness 2.6% NCT01608724 · Phase 4 · registry result, not featured evidence diabetes mellitus 6.5% (placebo 8.1%) dizziness 4.5% (placebo 4.2%) hypertension 4.2% (placebo 3.9%) NCT01107886 · Phase 4 · registry result, not featured evidence 5 mg nasopharyngitis 6.4% arthralgia 4.7% diarrhoea 4.2% NCT01006603 · Phase 4 · registry result, not featured evidence hypoglycaemia 6.8% diarrhoea 6.1% nasopharyngitis 5.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 5 mg toothache 7.7% (placebo 0%) acne 3.8% (placebo 0%) animal bite 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg aphthous ulcer 3.8% (placebo 0%) back pain 3.8% (placebo 2.6%) colitis 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 15.4% (placebo 2.6%) asthma 7.7% (placebo 0%) covid-19 7.7% (placebo 2.6%) NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.5 mg vitamin d deficiency 4.5% (placebo 6.6%) nausea 3.4% (placebo 0%) urinary tract infection 3.4% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg influenza 4.9% (placebo 2.6%) bronchitis 1.6% (placebo 0%) chronic sinusitis 1.6% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg covid-19 6.6% (placebo 2.6%) upper respiratory tract infection 6.6% (placebo 2.6%) urinary tract infection 4.9% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence dapagliflozin 10 mg, saxagliptin 5 mg urinary tract infection 13.7% upper respiratory tract infection 10.1% headache 7.9% NCT02419612 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.7% upper respiratory tract infection 5.2% headache 3.7% NCT02551874 · Phase 3 · registry result, not featured evidence · combination glomerular filtration rate decreased 4.1% pollakiuria 2.4% urinary tract infection 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on nasopharyngitis 7.8% headache 5.6% urinary tract infection 4.3% NCT02284893 · Phase 3 · registry result, not featured evidence · combination oropharyngeal pain 50% (placebo 25%) acne 25% (placebo 0%) cough 25% (placebo 25%) NCT01204775 · Phase 3 · registry result, not featured evidence headache 50% (placebo 0%) abdominal pain upper 25% (placebo 0%) back pain 25% (placebo 0%) NCT01434186 · Phase 3 · registry result, not featured evidence 5 mg QD hypoglycaemia 21.8% (placebo 23.8%) upper respiratory tract infection 2.6% (placebo 4.3%) urinary tract infection 2.6% (placebo 0.9%) NCT02104804 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 9.4% (placebo 10%) influenza 7.5% (placebo 7.5%) headache 6.9% (placebo 8.1%) NCT01646320 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.2% (placebo 6.8%) headache 5.9% (placebo 7.4%) nasopharyngitis 5.9% (placebo 4.9%) NCT01619059 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.2% (placebo 9.4%) diarrhoea 5.4% (placebo 3.9%) hypertension 5.4% (placebo 1.6%) NCT01128153 · Phase 3 · registry result, not featured evidence diarrhoea 5.8% urinary tract infection 5.1% nasopharyngitis 4.3% NCT00960076 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% diarrhoea 5.8% upper respiratory tract infection 5.8% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 8.4% (placebo 9.4%) NCT00918879 · Phase 3 · registry result, not featured evidence 5 mg + Metformin XR 1500 mg cough 6.5% NCT00918138 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.6% (placebo 7.9%) nasopharyngitis 6.3% (placebo 6.6%) upper respiratory tract infection 6.3% (placebo 7.3%) NCT00757588 · Phase 3 · registry result, not featured evidence · combination hypoglycaemia 28.2% (placebo 29.4%) anaemia 5.9% (placebo 8.2%) hypertension 5.9% (placebo 5.9%) NCT00614939 · Phase 3 · registry result, not featured evidence 5 mg headache 25% (placebo 18.8%) muscle spasms 25% (placebo 0%) infusion site pain 20% (placebo 12.5%) NCT00374907 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.3% (placebo 7.7%) NCT00698932 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.7% (placebo 4.5%) NCT00661362 · Phase 3 · registry result, not featured evidence · combination | h nasopharyngitis 19.8% (placebo 27.4%) upper respiratory tract inflammation 5.2% (placebo 7.4%) alanine aminotransferase increased 4.2% (placebo 3.2%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 23 more resultsnasopharyngitis 33.3% (placebo 27.4%) protein urine present 16.7% (placebo 13.7%) glucose urine present 11.5% (placebo 17.9%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 37.1% blood creatine phosphokinase increased 9.3% protein urine present 9.3% NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 32.6% glucose urine present 18% protein urine present 14.6% NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 28.6% (placebo 18.3%) hypoglycaemia 27.3% (placebo 7%) constipation 10.4% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 11.7% (placebo 7%) nasopharyngitis 7.8% (placebo 18.3%) constipation 3.9% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 11.3% (placebo 17.9%) hyperuricaemia 8.9% (placebo 10.6%) hyperlipidaemia 6.5% (placebo 5.7%) NCT02924064 · Phase 3 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 23.6% (placebo 15.7%) hyperuricaemia 8.7% (placebo 4.7%) proteinuria 7.1% (placebo 3.9%) NCT02916706 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 15.6% (placebo 10.4%) upper respiratory tract infection 5.2% (placebo 0%) NCT02354222 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.2% upper respiratory tract inflammation 9.4% blood urine present 7.1% NCT01301833 · Phase 3 · registry result, not featured evidence nasopharyngitis 28% upper respiratory tract inflammation 10.7% eczema 9.3% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.5% upper respiratory tract inflammation 10.5% blood urine present 9.5% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 23.8% upper respiratory tract inflammation 13.8% bronchitis 8.8% NCT01301833 · Phase 3 · registry result, not featured evidence · combination 20 mg nasopharyngitis 6.1% (placebo 0%) blood triglycerides increased 3% (placebo 3.1%) diarrhoea 3% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 10 mg upper respiratory tract inflammation 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 0%) alanine aminotransferase increased 2.9% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 12.1% (placebo 6.7%) glucose urine present 4% (placebo 6.7%) upper respiratory tract inflammation 4% (placebo 3.8%) NCT00998881 · Phase 3 · registry result, not featured evidence 40 mg nasopharyngitis 8% (placebo 6.8%) cystitis 5.7% (placebo 1.1%) gastroenteritis 3.4% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg diarrhoea 5.5% (placebo 3.4%) headache 5.5% (placebo 1.1%) hypertension 3.3% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 10 mg cystitis 4.3% (placebo 1.1%) nasopharyngitis 4.3% (placebo 6.8%) bronchitis 3.2% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 6.9% (placebo 6.8%) hypertension 5.7% (placebo 2.3%) bronchitis 3.4% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg nasopharyngitis 11.4% (placebo 13.8%) glucose urine present 5.1% (placebo 7.5%) urine ketone body present 5.1% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 19% (placebo 13.8%) blood creatine phosphokinase increased 4.8% (placebo 1.3%) blood urine present 4.8% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 17.3% (placebo 13.8%) arthropod sting 3.7% (placebo 0%) glucose urine present 3.7% (placebo 7.5%) NCT00628212 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cAssessment timepoints differ: 24 weeks versus 52 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTreatment context has not been resolved for both arms.
- fAssessment timepoints differ: 24 weeks versus 12 weeks.
- gPopulation comparability has not been reviewed for 38 of these studies.
- hPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Saxagliptin
show 8 more results
show 6 more results
show 15 more results
show 3 more results
show 4 more results
show 2 more results
show 7 more results
show 2 more results
show 1 more result
+ 43 further endpoints in the CSV export.
Teneligliptin
show 5 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Saxagliptin's landscape · Teneligliptin's landscape